These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 2205708

  • 1. Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of the oligodendrocyte-type 2 astrocyte lineage.
    Scolding NJ, Morgan BP, Campbell AK, Compston DA.
    J Neurol Sci; 1990 Jul; 97(2-3):155-62. PubMed ID: 2205708
    [Abstract] [Full Text] [Related]

  • 2. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.
    Scolding NJ, Morgan BP, Houston A, Campbell AK, Linington C, Compston DA.
    J Neurol Sci; 1989 Feb; 89(2-3):289-300. PubMed ID: 2926453
    [Abstract] [Full Text] [Related]

  • 3. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis.
    Piddlesden SJ, Morgan BP.
    J Neuroimmunol; 1993 Feb; 48(2):169-75. PubMed ID: 7693753
    [Abstract] [Full Text] [Related]

  • 4. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.
    Wren DR, Noble M.
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):9025-9. PubMed ID: 2813437
    [Abstract] [Full Text] [Related]

  • 5. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.
    Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS.
    Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum-mediated oligodendrocyte cytotoxicity in multiple sclerosis patients and controls.
    Hirayama M, Lisak RP, Silberberg DH.
    Neurology; 1986 Feb; 36(2):276-8. PubMed ID: 3945400
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg").
    Stangel M, Compston A, Scolding NJ.
    J Neuroimmunol; 2000 Mar 01; 103(2):195-201. PubMed ID: 10696915
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical study with an anti-myelin serum. A marker for all glial cells except 'dark' oligodendrocytes.
    Roussel G, Nussbaum JL.
    J Neuroimmunol; 1983 Dec 01; 5(3):209-26. PubMed ID: 6361066
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antibody-mediated oligodendrocyte cell death requires an astrocyte-derived cosignal.
    Zhou L, Miller RH.
    J Neurosci Res; 1998 Apr 15; 52(2):137-48. PubMed ID: 9579404
    [Abstract] [Full Text] [Related]

  • 18. Anti-heat shock protein 90beta antibodies decrease pre-oligodendrocyte population in perinatal and adult cell cultures. Implications for remyelination in multiple sclerosis.
    Cid C, Alvarez-Cermeño JC, Salinas M, Alcázar A.
    J Neurochem; 2005 Oct 15; 95(2):349-60. PubMed ID: 16135098
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. O-2A glial progenitors from mature brain respond to CNS neuronal cell line-derived growth factors.
    Hunter SF, Bottenstein JE.
    J Neurosci Res; 1991 Apr 15; 28(4):574-82. PubMed ID: 1870158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.